Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma

Stopped Update on clinical development: after discussions with the drug manufacturer, the PI has decided to discontinue the trial.

Conditions

• Neuroendocrine Tumors

Interventions

• DRUG: Pembrolizumab Injection

Sponsor

University of Utah

Collaborators

• [object Object]